Cefotetan versus Conventional Triple Antibiotic Prophylaxis in Elective Colorectal Cancer Surgery.
10.3346/jkms.2010.25.3.429
- Author:
Woon Kyung JEONG
1
;
Ji Won PARK
;
Seok Byung LIM
;
Hyo Seong CHOI
;
Seung Yong JEONG
Author Information
1. Department of Colon and Rectal Surgery, Sunlin Hospital, Pohang, Korea.
- Publication Type:Original Article
- Keywords:
Antibiotic Prophylaxis;
Colorectal Neoplasms;
Surgical Wound Infection;
Cefotetan
- MeSH:
Adolescent;
Adult;
Aged;
Aged, 80 and over;
Anti-Bacterial Agents/*therapeutic use;
*Antibiotic Prophylaxis;
Cefotetan/*therapeutic use;
Colorectal Neoplasms/*surgery;
Drug Therapy, Combination;
Humans;
Male;
Middle Aged;
Postoperative Complications/*prevention & control;
Surgical Wound Infection/*prevention & control;
Treatment Failure;
Treatment Outcome;
Young Adult
- From:Journal of Korean Medical Science
2010;25(3):429-434
- CountryRepublic of Korea
- Language:English
-
Abstract:
This study examined infectious outcomes in elective colorectal cancer surgery between cefotetan alone or conventional triple antibiotics. From January to December 2007, 461 consecutive primary colorectal cancer patients underwent elective surgery. Group A contained 225 patients who received conventional triple antibiotics (cephalosporin, aminoglycoside and metronidazole) for prophylaxis, and group B contained 236 patients who received cefotetan alone for prophylaxis. Treatment failure was defined as the presence of postoperative infection including surgical-site infection (SSI), anastomotic leakage, and pneumonia or urinary tract infection. The two groups were similar in terms of demographics, American Society of Anesthesiologists (ASA) score, tumour location, stage, surgical approach (conventional open vs. laparoscopy-assisted), and type of operation. The treatment failure rates were 3.1% in Group A and 3.4% in Group B (absolute difference, -0.3%; 95% confidence interval [CI], 0.39 to 3.07, P=0.866), with SSI being the most common reason for failure in both groups (2.7% in Group A and 3.0% in Group B [absolute difference, -0.3%; 95% CI, 0.37 to 3.37, P=0.846]). Cefotetan alone is as effective as triple antibiotics for prophylaxis in primary colorectal cancer patients undergoing elective surgery.
